EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

12-Lipoxygenase (12-LOX) plays a key role in the hyperinflammatory response caused by SARS-CoV-2

Melinee D'silva, Karen Jackson, Matthew T Vaughan, David J Maloney, Sachin A Gupte, Jerry L Nadler, Chandra Shekhar Bakshi iD

mBio · 10.06.2026 · 17 (6)

DOI: 10.1128/mbio.00738-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 10.06.2026. Verfasst von Melinee D'silva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, New York Medical College, Valhalla, New York, USA. Hauptthemen laut MEDLINE: COVID-19, Arachidonate 12-Lipoxygenase, Inflammation. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to significant global morbidity and mortality. The severe disease outcomes are often associated with a hyperinflammatory response known as a “cytokine storm.” The mechanisms underlying this exaggerated immune response remain incompletely understood. This study aimed to investigate the molecular pathways contributing to the severe inflammatory damage and mortality associated with COVID-19. SARS-CoV-2 hijacks host lipid metabolism, particularly the phospholipase A2 (PLA2) pathway, leading to the production of bioactive lipid mediators, including 12-lipoxygenase (12-LOX)-derived lipid mediators in platelets, and in lung and vascular cells. We hypothesized that 12-LOX drives the hyperinflammatory response and disease severity, and that its inhibition could reduce inflammation and improve outcomes. Analysis of autopsy lung samples from COVID-19 decedents and SARS-CoV-2-infected K18-hACE2 transgenic mice revealed increased 12-LOX expression. We evaluated VLX-1005, a selective small-molecule 12-LOX inhibitor, in infected mice. Treatment initiated 48 h post-infection significantly improved survival, reduced body weight loss, and decreased lung inflammation compared to controls. Notably, male mice showed higher survival rates than females. VLX-1005 treatment also suppressed key chemokines and cytokines associated with the cytokine storm, and reduced lung damage. These findings identify 12-LOX as a critical mediator of the hyperinflammatory response in severe COVID-19 and support its inhibition as a promising therapeutic strategy to mitigate inflammatory damage and reduce mortality. IMPORTANCE This study provides critical insights into the mechanisms underlying severe COVID-19, identifying 12-lipoxygenase (12-LOX) as a key driver of the hyperinflammatory response that contributes to disease severity and mortality. By demonstrating that SARS-CoV-2 hijacks host-lipid metabolism to elevate proinflammatory lipid mediators, the research uncovers a novel pathogenic pathway that exacerbates lung inflammation. The use of VLX-1005, a selective 12-LOX inhibitor, significantly improved survival and reduced inflammatory damage in a mouse model, highlighting its therapeutic potential. These findings not only deepen our understanding of COVID-19 pathogenesis but also position 12-LOX as a promising intervention target, offering a new avenue to mitigate the effects of cytokine storms in severe cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Arachidonate 12-LipoxygenaseInflammationAnimalsMiceSARS-CoV-2FemaleMaleMice, TransgenicHumansLungDisease Models, AnimalLipoxygenase InhibitorsCytokinesCytokine Release SyndromeLipid Metabolism

Stichwörter der Autor:innen

12-lipoxygenaseCOVID-19SARS-CoV-2cytokine storminflammation

Substanzen

Arachidonate 12-LipoxygenaseLipoxygenase InhibitorsCytokines

Autor:innen und Institutionen

  • Department of Pharmacology, New York Medical College, Valhalla, New York, USA.
  • Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, New York, USA.
  • School of Medicine, New York Medical College, Valhalla, New York, USA.
  • Veralox Therapeutics Inc., Frederick, Maryland, USA.
  • Research Service, Veteran Affairs, Northern California Health System, Sacramento, California, USA.

ORCID-Profile: Chandra Shekhar Bakshi

Zitieren

APA

D'silva, M., Jackson, K., Vaughan, M. T., Maloney, D. J., Gupte, S. A., Nadler, J. L., & Bakshi, C. S. (2026). 12-Lipoxygenase (12-LOX) plays a key role in the hyperinflammatory response caused by SARS-CoV-2. mBio, 17(6). https://doi.org/10.1128/mbio.00738-26

Vancouver

D'silva M, Jackson K, Vaughan MT, Maloney DJ, Gupte SA, Nadler JL, et al. 12-Lipoxygenase (12-LOX) plays a key role in the hyperinflammatory response caused by SARS-CoV-2. mBio. 2026;17(6). doi:10.1128/mbio.00738-26

BibTeX
@article{Dsilva2026,
  author = {D'silva, Melinee and Jackson, Karen and Vaughan, Matthew T and Maloney, David J and Gupte, Sachin A and Nadler, Jerry L and Bakshi, Chandra Shekhar},
  title = {12-Lipoxygenase (12-LOX) plays a key role in the hyperinflammatory response caused by SARS-CoV-2},
  journal = {mBio},
  year = {2026},
  volume = {17},
  number = {6},
  doi = {10.1128/mbio.00738-26}
}
Kostenlos starten →